Lipid-lowering therapy use and LDL-C goal achievement in patients with hypercholesterolaemia or mixed dyslipidaemia in Hong Kong: findings from a retrospective database study Authors: Bryan Yan1*, Minjung Kim2, Shuji Tsukiyama3, Angel Lai1 Affiliations:...
More
Lipid-lowering therapy use and LDL-C goal achievement in patients with hypercholesterolaemia or mixed dyslipidaemia in Hong Kong: findings from a retrospective database study Authors: Bryan Yan1*, Minjung Kim2, Shuji Tsukiyama3, Angel Lai1 Affiliations: 1Division of Cardiology, Department of Medicine & Therapeutics, The Chinese University of Hong Kong. 2Asia, South and Central America (ASCA) Oncology Product Department, Daiichi Sankyo Co., Ltd. 3 ASCA Primary Product Department, Daiichi Sankyo Co., Ltd. *Corresponding author Purpose Results Table 2 LLT usage and LDL-C goal achievement in the overall, statin-intolerant and • In the high– and very high–CV-risk groups • Despite strong guideline • Overall, 4,863,419 patients were identified during the statin-tolerant populations with high and very high CV riska in the overall study population, the LDL-C recommendations for intensive patient identification period, with 2,178,328 having 5 years Overall study population Statin-intolerant popu
Less
